Maculopapular eruption
|
Exanthem, rash, squamous papular, pityriasis rosea-like, erythema multiforme-like |
9%-47%2626 Casas CG, Català A, Hernández GC, Rodríguez-Jiménez P,Fernández-Nieto D, Lario ARV, et al. Classification of thecutaneous manifestations of COVID-19: a rapid prospectivenationwide consensus study in Spain with 375 cases. Br J Der-matol. 2020;183:71-7.
27 Masson A, Bouaziz JD, Sulimovic L, Cassius C, Jachiet M, Ionescu MA, et al. Chilblains is a common cutaneous finding duringthe COVID-19 pandemic: A retrospective nationwide study fromFrance. J Am Acad Dermatol. 2020;83:667-70.
28 Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C,Desai SR, et al. The spectrum of COVID-19-associated dermato-logic manifestations: An international registry of 716 patientsfrom 31 countries. J Am Acad Dermatol. 2020;83:1118-29.
29 Marzano AV, Genovese G, Moltrasio C, Gaspari V, Vezzoli P,Maione V, et al. The clinical spectrum of COVID-19-associatedcutaneous manifestations: An Italian multicenter study of 200adult patients. J Am Acad Dermatol. 2021;84:1356-63.-3030 Visconti A, Bataille V, Rossi N, Kluk J, Murphy R, Puig S, et al.Diagnostic value of cutaneous manifestation of SARS-CoV-2infection. Br J Dermatol. 2021;184:880-7.
|
Adults |
Mild |
0-14 days |
Erythema Pernio-like
|
Violaceous macules on the extremities at mild temperatures |
18%-75%2626 Casas CG, Català A, Hernández GC, Rodríguez-Jiménez P,Fernández-Nieto D, Lario ARV, et al. Classification of thecutaneous manifestations of COVID-19: a rapid prospectivenationwide consensus study in Spain with 375 cases. Br J Der-matol. 2020;183:71-7.
27 Masson A, Bouaziz JD, Sulimovic L, Cassius C, Jachiet M, Ionescu MA, et al. Chilblains is a common cutaneous finding duringthe COVID-19 pandemic: A retrospective nationwide study fromFrance. J Am Acad Dermatol. 2020;83:667-70.
28 Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C,Desai SR, et al. The spectrum of COVID-19-associated dermato-logic manifestations: An international registry of 716 patientsfrom 31 countries. J Am Acad Dermatol. 2020;83:1118-29.
29 Marzano AV, Genovese G, Moltrasio C, Gaspari V, Vezzoli P,Maione V, et al. The clinical spectrum of COVID-19-associatedcutaneous manifestations: An Italian multicenter study of 200adult patients. J Am Acad Dermatol. 2021;84:1356-63.-3030 Visconti A, Bataille V, Rossi N, Kluk J, Murphy R, Puig S, et al.Diagnostic value of cutaneous manifestation of SARS-CoV-2infection. Br J Dermatol. 2021;184:880-7.
|
Children and young individuals |
Mild or asymptomatic |
After 10-14 days |
Urticaria
|
Indistinguishable from other forms of urticaria, angioedema is rare |
9%-30%2626 Casas CG, Català A, Hernández GC, Rodríguez-Jiménez P,Fernández-Nieto D, Lario ARV, et al. Classification of thecutaneous manifestations of COVID-19: a rapid prospectivenationwide consensus study in Spain with 375 cases. Br J Der-matol. 2020;183:71-7.
27 Masson A, Bouaziz JD, Sulimovic L, Cassius C, Jachiet M, Ionescu MA, et al. Chilblains is a common cutaneous finding duringthe COVID-19 pandemic: A retrospective nationwide study fromFrance. J Am Acad Dermatol. 2020;83:667-70.
28 Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C,Desai SR, et al. The spectrum of COVID-19-associated dermato-logic manifestations: An international registry of 716 patientsfrom 31 countries. J Am Acad Dermatol. 2020;83:1118-29.
29 Marzano AV, Genovese G, Moltrasio C, Gaspari V, Vezzoli P,Maione V, et al. The clinical spectrum of COVID-19-associatedcutaneous manifestations: An Italian multicenter study of 200adult patients. J Am Acad Dermatol. 2021;84:1356-63.-3030 Visconti A, Bataille V, Rossi N, Kluk J, Murphy R, Puig S, et al.Diagnostic value of cutaneous manifestation of SARS-CoV-2infection. Br J Dermatol. 2021;184:880-7.
|
Adults |
Mild |
Pre or 0-14 days |
Vesico-bullous
|
Varicella-like |
9%-15%2626 Casas CG, Català A, Hernández GC, Rodríguez-Jiménez P,Fernández-Nieto D, Lario ARV, et al. Classification of thecutaneous manifestations of COVID-19: a rapid prospectivenationwide consensus study in Spain with 375 cases. Br J Der-matol. 2020;183:71-7.
27 Masson A, Bouaziz JD, Sulimovic L, Cassius C, Jachiet M, Ionescu MA, et al. Chilblains is a common cutaneous finding duringthe COVID-19 pandemic: A retrospective nationwide study fromFrance. J Am Acad Dermatol. 2020;83:667-70.
28 Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C,Desai SR, et al. The spectrum of COVID-19-associated dermato-logic manifestations: An international registry of 716 patientsfrom 31 countries. J Am Acad Dermatol. 2020;83:1118-29.
29 Marzano AV, Genovese G, Moltrasio C, Gaspari V, Vezzoli P,Maione V, et al. The clinical spectrum of COVID-19-associatedcutaneous manifestations: An Italian multicenter study of 200adult patients. J Am Acad Dermatol. 2021;84:1356-63.-3030 Visconti A, Bataille V, Rossi N, Kluk J, Murphy R, Puig S, et al.Diagnostic value of cutaneous manifestation of SARS-CoV-2infection. Br J Dermatol. 2021;184:880-7.
|
Adults |
Mild to moderate |
Pré or 0-7 days |
Livedo, purpura, necrosis
|
Fixed livedo reticularis, livedo racemosa; purpura, vasculitis; necrosis of extremities |
4%-9% 26-30 |
Elderly |
Severe |
After 10-14 days |